Tolerability of different oral iron supplements: A systematic review

Current Medical Research and Opinion

Volumn 29, Issue 4, 2013, Pages 291-303

  Cancelo Hidalgo, María Jesús ^a,b   Castelo Branco, Camil ^c   Palacios, Santiago ^d   Haya Palazuelos, Javier ^e   Ciria Recasens, Manel ^f   Manasanch, José ^g   Pérez Edo, Lluís ^e  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Palacios Institute of Woman's Health   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g Centre d'Immunologie Pierre Fabre   (France)

Author keywords

Adverse effects; Ferrous sulfate; Iron deficiency; Iron deficiency anemia; Mucoproteose; Iron tolerability

Indexed keywords

CARBONYL IRON; FERRIC CARBOXYMALTOSE; FERROUS CARBONATE; FERROUS FUMARATE; FERROUS GLUCONATE; FERROUS GLYCINE SULFATE; FERROUS SULFATE; FERROUS SULFATE PLUS MUCOPROTEOSE; GOSERELIN; IRON DERIVATIVE; IRON POLYMALTOSE; IRON PROTEIN SUCCINYLATE; IRON SACCHARATE; TARDYFERON; UNCLASSIFIED DRUG;

ANEMIA; DRUG FORMULATION; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANEMIA, IRON-DEFICIENCY; DIETARY SUPPLEMENTS; FERRIC COMPOUNDS; FERROUS COMPOUNDS; GLYCINE; HUMANS; METALLOPROTEINS; SUCCINATES;

EID: 84875162605     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.761599     Document Type: Review

References (129)

1. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet 2007;370:511-20
2. WHO Global Database on Anaemia. Worldwide prevalence of anaemia 1993-2005 Available at: http://whqlibdoc.who.int/publications/2008/rfpy1 9789241596657-eng.pdf
3. World Health Organization. Iron Deficiency Anaemia. Assessment, Prevention, and Control. A guide for programme managers. Geneva, World Health Organization, 2001 (WHO/NHD/01.3). Available at: http://www.who.int/nutrition/ publications/micronutrients/anaemia-iron-deficiency/WHO-NHD-01.3/en/index.html
4. World Health Organization. The World Health Report 2002: Reducing risks, promoting healthy life. Geneva: World Health Organization, 2002
5. Centers for Disease Control and Prevention. Recommendations to prevent and control iron deficiency in the United States. MMWR 1998 47;23-25
6. WHO Model Formulary 2008 (based on WHO Model List of Essential Medicines). Available at: http://www.who.int/selection-medicines/list/en/index. html
7. WHO. Model List of Essential Medicines. 16th edn. Update March 2010. Geneva, Switzerland. Available at: http://www.who.int/medicines/publications/ essentialmedicines/en/index.html
8. Dietzfelbinger H, Kaboth W. Investigations of the bioavailability of iron from biand trivalent iron salts. Med Klin 1977;72:654-9
9. Dietzfelbinger H, Kaboth W. Comparison of bio-availability, antianaemic efficacy, tolerance and drug costs in oral iron(II) and iron(III) preparations. Med Klin 1979;74:1818-24
10. Dietzfelbinger H. Bioavailability of bi-and trivalent oral iron preparations. Arzneimittelforschung 1987;37:107-112
11. Heinrich HC. Bioavailability of trivalent iron in oral iron preparations. Therapeutic efficacy and iron absorption from simple ferric compounds and high-or low-molecular weight ferric hydroxide-carbohydrate complexes. Arzneimittelforschung 1975;25:420-6
12. Jacobs P, Fransman D, Coghlan P. Comparative bioavailability of ferric polymaltose and ferrous sulfate in iron-deficient blood donors. J Clin Apher 1993;8:89-95
13. Kaltwasser JP, Werner E, Niechzial M. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneimittelforschung 1987;37:122-9
14. Nielsen P, Gabbe EE, Fischer R, et al. Bioavailability of iron from oral ferric polymaltose in humans. Arzneimittelforschung 1994;44:743-8
15. Pennell MD, Davies MI, Rasper J, Motzok I. Biological availability of iron supplements for rats, chicks and humans. J Nutr 1976;106:265-74
16. Todd T, Caroe T. Newly diagnosed iron deficiency anaemia in a premenopausal woman. BMJ 2007;334:259
17. Harju E. Clinical pharmacokinetics of iron preparations. Clin Pharmacokinet 1989;17:69-89
18. McDiarmid T, Johnson ED. Clinical inquiries. Are any oral iron formulations better tolerated than ferrous sulfate? J Fam Pract 2002;51:576
19. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology Am Soc Hematol Educ Program 2003;1:40-61
20. Aronoff GR. Safety of intravenous iron in clinical practice: implications for anemia management protocols. J Am Soc Nephrol 2004;15(Suppl 2): S99-106
21. Eckstein RP, Symons P. Iron tablets cause histopathologically distinctive lesions in mucosal biopsies of the stomach and esophagus. Pathology 1996;28:142-5
22. Boyce HW. Drug-induced esophageal damage: diseases of medical progress. Gastrointest Endosc 1998;47:547-50
23. Abraham SC, Yardley JH, Wu TT. Erosive injury to the upper gastrointestinal tract in patients receiving iron medication: an underrecognized entity. Am J Surg Pathol 1999;23:1241-7
24. Ji H, Yardley JH. Iron medication-associated gastric mucosal injury. Arch Pathol Lab Med 2004;128:821-2
25. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med 2008;121:943-8
26. Hansen CM. Oral iron supplements. Am Pharm 1994;NS34:66-71
27. Reveiz L, Gyte GM, Cuervo LG. Treatments for iron-deficiency anaemia in pregnancy. Cochrane Database Syst Rev 2007 Apr 18;(2):CD003094
28. Pena-Rosas JP, Viteri FE. Effects and safety of preventive oral iron or ironfolic acid supplementation for women during pregnancy. Cochrane Database Syst Rev 2009 Oct 7;(4):CD004736
29. Remacha AF, Canals C. La anemia en la gestacion. Haematologica 2006;91:189-195
30. Schumann K, Ettle T, Szegner B, et al. On risks and benefits of iron supplementation recommendations for iron intake revisited. J Trace Elem Med Biol 2007;21:147-68
31. Souza AI, Batista Filho M, Bresani CC, et al. Adherence and side effects of three ferrous sulfate treatment regimens on anemic pregnant women in clinical trials. Cad Saude Publica 2009;25:1225-33
32. Tessema J, Jefferds ME, Cogswell M, Carlton E. Motivators and barriers to prenatal supplement use among minority women in the United States. J Am Diet Assoc 2009;109:102-8
33. Gilmartin C. Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits. Am J Health Syst Pharm 2007;64:S15-22
34. Kopcke W, Sauerland MC. Meta-analysis of efficacy and tolerability data on iron protein succinylate in patients with iron deficiency anemia of different severity. Arzneimittelforschung 1995;45:1211-16
35. Blanc B, Magnenat P, Delaloyle B. Factors affecting the bonding of iron and their influence on absorption and metabolism. In: Hallberg HG, Vannoti A, eds. Iron deficiency. Pathogenesis-Clinical Aspects-Therapy. London, New York: Academic Press, 1970:135-50
36. Mitchell ABS. Oral iron tolerance. Postgrad Med J 1974;50:702-6
37. Hallberg L, Bjorn-Rasmussen E, Ekenved G, et al. Absorption from iron tablets given with different types of meals. Scand J Haematol. 1978;21:215-24
38. Schindler VH, Bielesz G. Treatment of iron deficiency with orally administered delayed-action ferrous sulfate and mucoproteose. Wien Med Wochenschr 1975;125:173-6
39. Hallberg L, Ryttinger L, Solvell L. Side-effects of oral iron therapy. Acta Med Scand Suppl 1966;459:3-10
40. Symonds EM, Radden HS, Cellier KM. Controlled-release iron therapy in pregnancy. Aust N Z J Obstet Gynaecol 1969;9:21-5
41. Elwood PC, Williams G. A comparative trial of slow-release and conventional iron preparations. Practitioner 1970;204:812-5
42. Aronstam A, Aston DL. A comparative trial of a controlled-release iron tablet preparation ('Ferrocontin' Continus) and ferrous fumarate tablets. Pharmatherapeutica 1982;3:263-7
43. Milman N, Byg KE, Bergholt T, et al. Side effects of oral iron prophylaxis in pregnancy-myth or reality? Acta Haematol 2006;115:53-7
44. Metzger KH. A new oral iron preparation with a new concept. Fortschr Med 1978;96:779-82
45. IMS Health Research. Medical Prescriptions Study. Analysis by form and posology for Spain, 2011:Jan-March:64-5
46. Collet D. Modelling Binary Data. London: Chapman and Hall, 2003
47. Chappuis F, Rijal S, Soto A, et al. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 2006;333:723
48. McCullagh P, Nelder JA. Generalized Linear Models, 2nd edn. London: Chapman & Hall, 1989:124-8
49. R Development Core Team. R: A language and environment for statistical computing. In: R foundation for statistical computing, Vienna, Austria, 2004. At www.R-project.org (accessed February 2011)
50. Kerr DN, Davidson S. The prophylaxis of iron-deficiency anaemia in pregnancy. Lancet 1958;2:483-8
51. Hood Jr WE, Bond WL. Iron deficiency prophylaxis during pregnancy. Obstet Gynecol 1960;16:82-4
52. Kirchhoff HW. Vertragliches Eisen in Depotform. Ergebnisse einer kontrollierten Vergleichsstudie. Arztl Prax 1978;30:1742-4
53. Levy F, Andersen P, Ekren T. Absorption and side-effects after peroral administration of sustained release tablets. Acta Med Scand 1978;204:303-10
54. Leslie J. A comparative trial of a new controlled-release iron tablet (Ferrocontin) and a slow-release ferrous sulphate preparation (Feospan Spansule capsules). Clinical Trials J 1979;16:2-4
55. Sas G, Nemesanszky E, Brauer H, et al. On the therapeutic effects of trivalent and divalent iron in iron deficiency anaemia. Arzneimittelforschung 1984;34:1575-9
56. Brock C, Curry H, Hanna C, et al. Adverse effects of iron supplementation: a comparative trial of a wax-matrix iron preparation and conventional ferrous sulfate tablets. Clin Ther 1985;7:568-73
57. Gordeuk VR, Brittenham GM, Hughes M, et al. High-dose carbonyl iron for iron deficiency anemia: a randomized double-blind trial. Am J Clin Nutr 1987;46:1029-34
58. Coplin M, Schuette S, Leichtmann G, et al. Tolerability of iron: a comparison of bis-glycino iron II and ferrous sulfate. Clin Ther 1991;13:606-12
59. Devasthali SD, Gordeuk VR, Brittenham GM, et al. Bioavailability of carbonyl iron: a randomized, double-blind study. Eur J Haematol 1991;46:272-8
60. Liguori L. Iron protein succinylate in the treatment of iron deficiency: controlled, double-blind, multicenter clinical trial on over 1000 patients. Int J Clin Pharmacol Ther Toxicol 1993;31:105-23
61. Al-Momen AK, al-Meshari A, al-Nuaim L, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 1996;69:121-4
62. Bruner AB, Joffe A, Duggan AK, et al. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 1996;348:992-6
63. Casparis D, Del Carlo P, Branconi F, et al. Efficacia e tollerabilitadel gluconato ferroso orale liquido nell'anemia da carenza da ferro in gravidanza e nell'immediato post-partum: confronto con altre formulazioni liquide o solide contenenti ferro bivalente o trivalente. Minerva Ginecol 1996;48:511-18
64. Ekstrom EC, Kavishe FP, Habicht JP, et al. Adherence to iron supplementation during pregnancy in Tanzania: determinants and hematologic consequences. Am J Clin Nutr 1996;64:368-74
65. Surico G, Ciruzzi F, Miniello VL, et al. Curva da carico orale di ferro: confronto fra due preparati, ferro solfato e ferro gluconato. Riv Ital Pediatr 1998;24:1124-6
66. Jacobs P, Wood L, Bird AR. Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology 2000;5:77-83
67. Pujol Farriols R, Anglada Oriol M, Formiga Perez F, et al. Hierro proteinsuccinilato para el tratamiento de la anemia ferropenica del adulto. An Med Interna 2002;19:651-2
68. Ahmed P, Mahmood A, Aziz S, et al. Comparison of response between food supplemented with powdered iron and iron in syrup form for iron deficiency anemia. J Coll Physicians Surg Pak 2003;13:402-4
69. Makrides M, Crowther CA, Gibson RA, et al. Efficacy and tolerability of lowdose iron supplements during pregnancy: a randomized controlled trial. Am J Clin Nutr 2003;78:145-53
70. de Silva AD, Tsironi E, Feakins RM, et al. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther 2005;22:1097-105
71. Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysisdependent CKD. Kidney Int 2005;68:2846-56
72. Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006;26:445-54
73. Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. BJOG 2006;113:1248-52
74. Christofides A, Asante KP, Schauer C, et al. Multi-micronutrient Sprinkles including a low dose of iron provided as microencapsulated ferrous fumarate improves haematologic indices in anaemic children: a randomized clinical trial. Matern Child Nutr 2006;2:169-80
75. Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol 2007;110:267-78
76. Melamed N, Ben-Haroush A, Kaplan B, et al. Iron supplementation in pregnancy-does the preparation matter? Arch Gynecol Obstet 2007;276:601-4
77. Muneyyirci-Delale O, Richard-Davis G, Morris T, et al. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial. Clin Ther 2007;29:1682-91
78. Breymann C, Gliga F, Bejenariu C, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet 2008;101:67-73
79. Westad S, Backe B, Salvesen KA, et al. A 12-week randomised study comparing intravenous iron sucrose versus oral ferrous sulphate for treatment of postpartum anemia. Acta Obstet Gynecol Scand 2008;87:916-23
80. Siegenthaler R. Klinische Prufung des Eisenpraparates FS I69 (Tardyferon-). Basel: Dokumentationsdossier Robapharm AG, 1972
81. Largiader A. Essai clinique des dragees retard Tardyferon. Schweiz Rundsch Med Prax 1973;62:578-82
82. Kozlowska F. Behandlung der Eisenmangelanamien mit Tardyferon. Schweiz Rundsch Med Prax 1974;63:1092-7
83. Holowiecki J, Stella-Holowiecka B, Harbut-Grylka A. Tardyferon-depot w leczeniu niedokrwistosci z neidoboru zelaza. Acta Haematol Pol 1976;7: 321-5
84. SchusseleA, Petite J, Guinard D. Behandlung der Eisenmangelanamie mit Tardyferon. Schweiz Rundschau Med Prax 1976;65:245-51
85. D?az-Rubio Garc?a M, D?az-Rubio Garc?a E. Ensayo cl?nico con el producto FS169 en las anemias sideropenicas. Med Clin (Barc) 1976;66:246-7
86. Draganski K. Klinische Beurteilung von Tardyferon, einem Eisendepotpraparat. Wien Med Wochenschr 1977;127:714-17
87. Hauser GA. Carence en fer et en acide folique durant la grossesse. Schweiz Rundsch Med Prax 1977;35:1127-31
88. Thomann F. Fortschittliche orale Eisentherapie. Therapiewoche 1977;27:5315-23
89. Germann M, Ginsheim-Gustavsburg. Problemloseorale eisen-langzeittherapie. Med Welt 1978;29:1904-5
90. Muldner H. Oral Eisentherapie: ein neues erfolgreiches Konzept. Z Allg Med 1978;54: 545-53
91. Popko J, Slowikowska J, Bogdanikowa B. The treatment of hypochromic anaemias with an iron depot preparation. Ars Medici 1978;11:519-20
92. Steger W. Neue Aspekte oraler Eisensubstitution. Therapiewoche 1978;28:9156-62
93. Hellerer O, Bruckner WL, Beitz T, et al. Eisenresorption nach Gastrektomie unter Tardyferon-Medikation. Med Klin 1978;73:1543-8
94. Oehlert G, Bandar A. Iron deficiency and oral substitution. Arztl Prax 1978;30:26-7
95. Muldner H, Steger W. Ergebnisse einer Tardyferon-Doppelblindstudie. Therapiewoche 1979;29:3014-21
96. Gerlach E. Effektvolle eisentherapie mit neuem konzept. Z Allg Med 1979;55:255-8
97. Gaultier M. Une nouvelle therapeutique des anemies hypochromes. Gaz Med Fr 1979;86:61-63
98. Junck GU. A reliable method of iron and folic acid substitution during pregnancy. Therapiewoche 1980;30:7188-93
99. Buzi E, Siegenthaler P. Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique. Schweiz Rundsch Med Prax 1980;47:1744-7
100. Bernat IS, Konc J, Hollan Z. A Tardyferon terapias hatekonysaga es a mellekhatasok elofordulasi gyakorisaga. Gyogyszereink 1984;34:239-43
101. Ifrah N, Houssin A, Girault P, et al. Apport de fer oral au cours des hemodialyses chroniques. Gazette Med 1986;93:72-4
102. Pengloan J, Abaza M. Effet de l'apport martial en prise unique chez l'hemodialyse chronique. Revue Med Tours 1986;20:344-6
103. Pejtsik B. Eisenmangei bei schwangeren und nichtschwangeren Frauen. In: Kaltwasser JP, Roetz R, eds. Eisenstoffwechsel-Grundlagen und Probleme, eds. Frankfurt: pmi Verlag, 1987
104. Bernard W, Geier FP. Efficacy and safety of a slow-release ferrous sulphate preparation in geriatric patients with iron deficiency anaemia. Z Geriatrie 1989;2:1-11
105. Mara M, Zivny J, Eretova V, et al. Changes in markers of anemia and iron metabolism and how they are influenced by antianemics in postpartum period. Acta Obstet Gynecol Scand 2001;80:142-8
106. Krafft A, Perewusnyk G, Hanseler E, et al. Effect of postpartum iron supplementation on red cell and iron parameters in non-anaemic iron-deficient women: a randomised placebo-controlled study. BJOG 2005;112:445-50
107. Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol 2008;38:20-6
108. De Renzo A, Buffardi S, Frigeri F, et al. Studio di efficacia e tollerabilitadel ferroproteinsuccinilato verso ferritina nell'anemia sideropenica. Recenti Prog Med 1987;78:562-5
109. Scremin S, Caprioglio L. Studio di efficacia e tollerabilitadel ferro proteinsuccinilato nella carenza marziale. Boll Chim Farm 1988;127:44-9S
110. Sallusto A, Eandi M, De Bartolo G, et al. [Ferroprotein succinylate: treatment of iron deficiency in obstetrics and gynecology]. Minerva Ginecol 1990;42:191-5
111. Careddu P, Scotti A. Controlled, double-blind, multicenter clinical trial of iron protein succinylate in the treatment of iron deficiency in children. Int J Clin Pharmacol Ther Toxicol 1993;31:157-69
112. Haliotis FA, Papanastasiou DA. Comparative study of tolerability and efficacy of iron protein succinylate versus iron hydroxide polymaltose complex in the treatment of iron deficiency in children. Int J Clin Pharmacol Ther 1998;36:320-5
113. Juarez-Vazquez J, Bonizzoni E, Scotti A. Iron plus folate is more effective than iron alone in the treatment of iron deficiency anaemia in pregnancy: a randomised, double blind clinical trial. BJOG 2002;109:1009-14
114. Black GS. A comparison of two iron tablet preparations in the treatment of iron deficiency anemia. J Int Med Res 1981;9:295
115. Adsul BB, Desai A, Gawde A, et al. Comparative assessment of the bioavailability, efficacy and safety of a modified-release (MR) carbonyl iron tablet and oral conventional iron preparation in adult Indian patients with nutritional iron deficiency anaemia. J Indian Med Assoc 2005;103:338-42
116. Liu TC, Lin SF, Chang CS, et al. Comparison of a combination ferrous fumarate product and a polysaccharide iron complex as oral treatments of iron deficiency anemia: a Taiwanese study. Int J Hematol 2004;80:416-20
117. Kavakli K, Yilmaz D, Cetinkaya B, et al. Safety profiles of Fe2 and Fe3 oral preparations in the treatment of iron deficiency anemia in children. Pediatr Hematol Oncol 2004;21:403-10
118. Radtke H, Mayer B, Rocker L, et al. Iron supplementation and 2-unit red blood cell apheresis: a randomized, double-blind, placebo-controlled study. Transfusion 2004;44:1463-7
119. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Lowdose iron therapy is effective in octogenarians. Am J Med 2005;118:1142-7
120. Wall CR, Grant CC, Taua N, et al. Milk versus medicine for the treatment of iron deficiency anaemia in hospitalised infants. Arch Dis Child 2005;90:1033-8
121. Horvath K, Horn G. Tardyferon therapy in hyposiderosis of infancy and childhood. Ther Hung 1992;40:40-3
122. Fadeenko GD, Kushnir IE. Tardyferon in the treatment of iron deficiency anaemia: clinical efficacy and safety. Suchasna Gastroenterologia 2009;5:74-80
123. Nielsen P, Kongi R, Fischer R. Efficacy of a prolonged-release iron preparation in iron deficiency. Abstract ID 433
124. Kim YK, Park SM, Kim CS. Effect of mucoproteose on aspirin induced gastric mucosal lesions in rats. Korean J Gastroenterol 1984;16:33-4
125. Lacerte P, Pradipasen M, Temcharoen P, et al. Determinants of adherence to iron/folate supplementation during pregnancy in two provinces in Cambodia. Asia Pac J Public Health 2011;23:315-23
126. Viteri FE. Iron supplementation for the control of iron deficiency in populations at risk. Nutr Rev 1997;55:195-209
127. Bilenko N, Yehiel M, Inbar Y, et al. The association between anemia in infants, and maternal knowledge and adherence to iron supplementation in southern Israel. Isr Med Assoc J 2007;9:521-4
128. Lachance K, Savoie M, Bernard M, et al. Oral ferrous sulfate does not increase preoperative hemoglobin in patients scheduled for hip or knee arthroplasty. Ann Pharmacother 2011;45:764-70
129. Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409-20